MDRAAC
The feature of our product antibody- antibiotic conjugate drugs is that two different drugs can be bonded to the antibody to provide a feasible strategy for bacterial resistance. Our product mainly targets patients with recurrent infection caused by Klebsiella pneumoniae, and combines the antibiotics and antibody-antibiotic conjugated drugs development.
MDRAAC
Industry:
Health Care
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Status:
Active
Contact:
+886-937833365
Email Addresses:
[email protected]
Founder
Wei-Kuang Chi
Newest Events participated
Participated in CES Las Vegas 2022
on 2022-01-05 as exhibitor